Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Recombinant Fusion Proteins"" wg kryterium: Wszystkie pola

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 19502
Tytuł:
Evolution-guided engineering of trans -acyltransferase polyketide synthases.
Autorzy:
Mabesoone MFJ; Institute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.
Leopold-Messer S; Institute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.
Minas HA; Institute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.
Chepkirui C; Institute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.
Chawengrum P; Institute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.; Chemical Biology Program, Chulabhorn Graduate Institute, Chulabhorn Royal Academy, Bangkok 10210, Thailand.
Reiter S; Institute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.
Meoded RA; Institute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.
Wolf S; Institute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.
Genz F; Institute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.
Magnus N; Institute for Biological Sciences, University of Rostock, Albert-Einstein-Straße 3, 18059 Rostock, Germany.
Piechulla B; Institute for Biological Sciences, University of Rostock, Albert-Einstein-Straße 3, 18059 Rostock, Germany.
Walker AS; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA.; Department of Chemistry, Vanderbilt University, 1234 Stevenson Center Lane, Nashville, TN 37240, USA.; Department of Biological Sciences, Vanderbilt University, 465 21st Avenue S, Nashville, TN 37232, USA.
Piel J; Institute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Mar 22; Vol. 383 (6689), pp. 1312-1317. Date of Electronic Publication: 2024 Mar 21.
Typ publikacji:
Journal Article
MeSH Terms:
Acyltransferases*/genetics
Acyltransferases*/chemistry
Polyketide Synthases*/chemistry
Polyketide Synthases*/genetics
Polyketides*/chemistry
Directed Molecular Evolution*
Bacterial Proteins*/chemistry
Bacterial Proteins*/genetics
Recombinant Fusion Proteins*/chemistry
Recombinant Fusion Proteins*/genetics
Serratia ; Amino Acid Motifs
SCR Organism:
Serratia plymuthica
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.
Autorzy:
Lim SY; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Lee J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Osuna CE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Vikhe P; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Schalk DR; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Chen E; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Fray E; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Kumar M; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Schultz-Darken N; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Rakasz E; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Capuano S; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Ladd RA; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Gil HM; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Evans DT; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Jeng EK; Altor Biosciences, Miramar, FL 33027, USA.
Seaman M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Martin M; Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Van Dorp C; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Perelson AS; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.; Santa Fe Institute, Santa Fe, NM 87501, USA.
Wong HC; Altor Biosciences, Miramar, FL 33027, USA.
Siliciano JD; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Siliciano R; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Safrit JT; ImmunityBio, Culver City, CA 90232, USA.
Nixon DF; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Soon-Shiong P; ImmunityBio, Culver City, CA 90232, USA.
Nussenzweig M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.; Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.
Whitney JB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.; Department of Biology, Boston College, Chestnut Hill, MA 02467, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Mar 08; Vol. 383 (6687), pp. 1104-1111. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-Retroviral Agents*/therapeutic use
Anti-Retroviral Agents*/pharmacology
Simian Acquired Immunodeficiency Syndrome*/drug therapy
Simian Acquired Immunodeficiency Syndrome*/therapy
Simian Immunodeficiency Virus*
Recombinant Fusion Proteins*/administration & dosage
Recombinant Fusion Proteins*/pharmacology
Animals ; Humans ; Broadly Neutralizing Antibodies/administration & dosage ; CD8-Positive T-Lymphocytes/virology ; Immunotherapy ; Macaca mulatta ; Viral Load ; Remission Induction ; Drug Therapy, Combination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical effects of atorvastatin combined with conbercept in the treatment of patients with macular edema secondary to retinal vein occlusion and carotid plaque: study protocol for a prospective randomized controlled trial.
Autorzy:
Yao B; Department of Ophthalmology, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui branch, Southeast University, Nanjing, Jiangsu Province, China. yaobamtao_.
Wang B; Department of Ophthalmology, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui branch, Southeast University, Nanjing, Jiangsu Province, China.
Yang J; Department of Neurology, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui branch, Southeast University, Nanjing, Jiangsu Province, China.
Geng Y; Department of Endocrinology, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui branch, Southeast University, Nanjing, Jiangsu Province, China.
Yu H; Department of Ophthalmology, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui branch, Southeast University, Nanjing, Jiangsu Province, China.
Liu Y; Department of Ophthalmology, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui branch, Southeast University, Nanjing, Jiangsu Province, China.
Liu G; Department of Ophthalmology, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui branch, Southeast University, Nanjing, Jiangsu Province, China.
Wang X; Department of Ophthalmology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China. wangxiuying_.
Pokaż więcej
Źródło:
Trials [Trials] 2024 Apr 08; Vol. 25 (1), pp. 244. Date of Electronic Publication: 2024 Apr 08.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Macular Edema*/diagnosis
Macular Edema*/drug therapy
Macular Edema*/etiology
Retinal Vein Occlusion*/complications
Retinal Vein Occlusion*/diagnosis
Retinal Vein Occlusion*/drug therapy
Recombinant Fusion Proteins*
Humans ; Angiogenesis Inhibitors ; Atorvastatin/adverse effects ; Prospective Studies ; Treatment Outcome ; Tomography, Optical Coherence ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review.
Autorzy:
Fan Q; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ji H; Department of Dermatology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liu Y; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jia C; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zou L; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yang H; Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pokaż więcej
Źródło:
Lupus [Lupus] 2024 Apr; Vol. 33 (4), pp. 414-419. Date of Electronic Publication: 2024 Feb 06.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Lupus Erythematosus, Systemic*/complications
Lupus Erythematosus, Systemic*/drug therapy
Hepatitis*/drug therapy
Recombinant Fusion Proteins*
Antibodies, Monoclonal, Humanized*
Humans ; Prospective Studies ; Treatment Outcome ; Immunosuppressive Agents/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effects of aflibercept and bevacizumab on cell viability, cell metabolism and inflammation in hypoxic human Müller cells.
Autorzy:
Matsuda M; Laboratory of Investigation in Ophthalmology (LIM-33), Division of Ophthalmology, School of Medicine, University of São Paulo, São Paulo, SP, Brazil.; Department of Cell & Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
da Silva RA; Department of Cell & Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Roda VMP; Department of Cell & Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Marquezini MV; Laboratory of Investigation in Ophthalmology (LIM-33), Division of Ophthalmology, School of Medicine, University of São Paulo, São Paulo, SP, Brazil.
Monteiro MLR; Laboratory of Investigation in Ophthalmology (LIM-33), Division of Ophthalmology, School of Medicine, University of São Paulo, São Paulo, SP, Brazil.
Hamassaki DE; Department of Cell & Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Mar 27; Vol. 19 (3), pp. e0300370. Date of Electronic Publication: 2024 Mar 27 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Vascular Endothelial Growth Factor A*/metabolism
Ependymoglial Cells*/metabolism
Recombinant Fusion Proteins*
Receptors, Vascular Endothelial Growth Factor*
Humans ; Bevacizumab/pharmacology ; Bevacizumab/metabolism ; Cell Survival ; Becaplermin/metabolism ; Tumor Necrosis Factor-alpha/metabolism ; Interleukin-8/metabolism ; Interleukin-6/metabolism ; Vascular Endothelial Growth Factors/metabolism ; Cytokines/metabolism ; Hypoxia/metabolism ; Neovascularization, Pathologic/pathology ; Inflammation/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry.
Autorzy:
Kishnani PS; Department of Pediatrics, Duke University Medical Center, 2351 Erwin Road, Durham, NC, 27710, USA. .
Martos-Moreno GÁ; Hospital Infantil Universitario Niño Jesús, IIS La Princesa, Universidad Autónoma de Madrid, CIBERobn, ISCIII, Madrid, Spain.
Linglart A; Paris-Saclay University, AP-HP and INSERM, Paris, France.
Petryk A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Messali A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Fang S; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Rockman-Greenberg C; University of Manitoba, Winnipeg, MB, Canada.
Ozono K; Osaka University, Suita, Osaka, Japan.
Högler W; Johannes Kepler University Linz, Linz, Austria.
Seefried L; University of Würzburg, Würzburg, Germany.
Dahir KM; Vanderbilt University Medical Center, Nashville, TN, USA.
Pokaż więcej
Źródło:
Orphanet journal of rare diseases [Orphanet J Rare Dis] 2024 Mar 08; Vol. 19 (1), pp. 109. Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Journal Article
MeSH Terms:
Hypophosphatasia*/drug therapy
Chronic Pain*
Immunoglobulin G*
Recombinant Fusion Proteins*
Adult ; Humans ; Alkaline Phosphatase/therapeutic use ; Quality of Life ; Prospective Studies ; Registries ; Enzyme Replacement Therapy/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dulaglutide treatment reverses depression-like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress.
Autorzy:
Jin M; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Zhang S; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Huang B; Neuroscience Research Center, Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang, China.
Li L; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Liang H; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.; Cardiology Department, Hebei General Hospital, Shijiazhuang, China.
Ni A; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Han L; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Liang P; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Liu J; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Shi H; Nursing School, Hebei Medical University, Shijiazhuang, China.
Lv P; Department of Neurology, Hebei Medical University, Shijiazhuang, China.; Department of Neurology, Hebei General Hospital, Shijiazhuang, China.; Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Shijiazhuang, China.
Pokaż więcej
Źródło:
Brain and behavior [Brain Behav] 2024 Mar; Vol. 14 (3), pp. e3448.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Depression*/drug therapy
Antidepressive Agents*/pharmacology
Antidepressive Agents*/therapeutic use
Immunoglobulin Fc Fragments*
Recombinant Fusion Proteins*
Glucagon-Like Peptides/*analogs & derivatives
Animals ; Mice ; Homeostasis ; Biomarkers
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
Autorzy:
Huang L; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Qian G; Department of Cardiovascular Medicine, Center for Circadian Metabolism and Cardiovascular Disease, The First Affiliated Hospital of Army Medical University, Chongqing, China.
Zhang H; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Li Q; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Chen L; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Tang X; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Zhao H; Nephrology Department of the First Affiliated Hospital of Army Medical University, Chongqing, China.
Pokaż więcej
Źródło:
Lupus [Lupus] 2024 Feb; Vol. 33 (2), pp. 172-175. Date of Electronic Publication: 2023 Dec 11.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Lupus Erythematosus, Systemic*/drug therapy
Lupus Nephritis*/drug therapy
Recombinant Fusion Proteins*
Humans ; Female ; Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; Treatment Outcome ; Immunosuppressive Agents/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of polyp regression and reduction on treatment efficacy in polypoidal choroidal vasculopathy treated with aflibercept.
Autorzy:
Sayanagi K; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan. .
Fujimoto S; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Hara C; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Fukushima Y; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Maruyama K; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Kawasaki R; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Sato S; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Nishida K; Department of Ophthalmology E7, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Jan 21; Vol. 14 (1), pp. 1833. Date of Electronic Publication: 2024 Jan 21.
Typ publikacji:
Journal Article
MeSH Terms:
Macula Lutea*
Polyps*/drug therapy
Recombinant Fusion Proteins*
Receptors, Vascular Endothelial Growth Factor*
Humans ; Polypoidal Choroidal Vasculopathy ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
IL-15 and N-803 for HIV Cure Approaches.
Autorzy:
Howard JN; Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC 20037, USA.
Bosque A; Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC 20037, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Sep 12; Vol. 15 (9). Date of Electronic Publication: 2023 Sep 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
HIV Infections*/drug therapy
HIV-1*/physiology
Recombinant Fusion Proteins*
Humans ; Virus Latency ; Interleukin-15 ; CD4-Positive T-Lymphocytes ; Virus Activation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting NKG2DL with Bispecific NKG2D-CD16 and NKG2D-CD3 Fusion Proteins on Triple-Negative Breast Cancer.
Autorzy:
Kaidun P; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Holzmayer SJ; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Greiner SM; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Seller A; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Tegeler CM; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Hagelstein I; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Mauermann J; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Engler T; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Koch A; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Hartkopf AD; Department of Obstetrics and Gynecology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Salih HR; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Märklin M; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, 72076 Tuebingen, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University Tuebingen, 72074 Tuebingen, Germany.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Aug 24; Vol. 24 (17). Date of Electronic Publication: 2023 Aug 24.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Recombinant Fusion Proteins*/therapeutic use
Humans ; Administration, Cutaneous ; Aggression ; Ligands ; NK Cell Lectin-Like Receptor Subfamily K/genetics ; Receptors, IgG ; CD3 Complex
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of Aflibercept for the treatment of inflammatory choroidal neovascularization: The ALINEA study.
Autorzy:
Kodjikian L; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; Université Lyon 1, Lyon, France.; UMR5510 MATEIS, CNRS, INSA Lyon, Université Lyon 1, Villeurbanne, France.
Abukhashabah A; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; Ophthalmology Department, King Abdulaziz University, Rabigh, Saudi Arabia.
Fardeau C; Ophthalmology Department, Reference Center for Rare Diseases, La Pitié-Salpêtriètre Hospital, Paris-Sorbonne University, Paris, France.
Tadayoni R; Université de Paris, Service d'Ophtalmologie, AP-HP, Hôpital Lariboisière, Paris, France.; Service d'Ophtalmologie, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.
Brézin A; Hôpital Cochin, Service d'Ophtalmologie, Université de Paris, Paris, France.
Dumas S; Centre Nordretine, Lille, France.
Weber M; Hôpital Universitaire Centre Nantes, Nantes, France.
Bernard L; Université Lyon 1, Lyon, France.; Pôle de Santé Publique, Service de Biostatistique et Bioinformatique, Hospices Civils de Lyon, Lyon, France.; CNRS, UMR5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbane, France.
Loria O; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; UMR5510 MATEIS, CNRS, INSA Lyon, Université Lyon 1, Villeurbanne, France.
Decullier E; Pôle de Santé Publique, Service Recherche et Epidémiologie Cliniques, Hospices Civils de Lyon, Lyon, France.
Huot L; Université Lyon 1, Lyon, France.; Pôle de Santé Publique, Service Recherche et Epidémiologie Cliniques, Hospices Civils de Lyon, Lyon, France.
Mathis T; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; Université Lyon 1, Lyon, France.; UMR5510 MATEIS, CNRS, INSA Lyon, Université Lyon 1, Villeurbanne, France.
Pokaż więcej
Źródło:
Acta ophthalmologica [Acta Ophthalmol] 2023 Feb; Vol. 101 (1), pp. e43-e49. Date of Electronic Publication: 2022 Jul 13.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Angiogenesis Inhibitors*/administration & dosage
Angiogenesis Inhibitors*/adverse effects
Choroidal Neovascularization*/drug therapy
Receptors, Vascular Endothelial Growth Factor*/administration & dosage
Recombinant Fusion Proteins*/administration & dosage
Recombinant Fusion Proteins*/adverse effects
Humans ; Intravitreal Injections ; Prospective Studies ; Treatment Outcome ; Visual Acuity
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Integrin Targeting Enhances the Antimelanoma Effect of Annexin V in Mice.
Autorzy:
Zhu J; Beijing Key Lab of Biotechnology and Genetic Engineering, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Li X; College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Gao W; College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Jing J; Beijing Key Lab of Biotechnology and Genetic Engineering, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Feb 15; Vol. 24 (4). Date of Electronic Publication: 2023 Feb 15.
Typ publikacji:
Journal Article
MeSH Terms:
Annexin A5*/therapeutic use
Integrin alpha1beta1*/metabolism
Melanoma*/therapy
Recombinant Fusion Proteins*/therapeutic use
Skin Neoplasms*/therapy
Animals ; Humans ; Mice ; Melanoma, Experimental ; Melanoma, Cutaneous Malignant
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Changes in Serum Concentrations of Vascular Endothelial Growth Factors-A and B after Intravitreal Injection of Ranibizumab and Conbercept for Retinopathy of Prematurity.
Autorzy:
Zhang H; Department of Ophthalmology of Henan Provincial People's Hospital, Henan Eye Hospital, Henan Eye Institute, People's Hospital of Zhengzhou University, Zhengzhou, China.
Yang X; Department of Ophthalmology of Henan Provincial People's Hospital, Henan Eye Hospital, Henan Eye Institute, People's Hospital of Zhengzhou University, Zhengzhou, China.
Zheng F; Neonatal Intensive Care Unit of Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
Wan S; Department of Ophthalmology of Henan Provincial People's Hospital, Henan Eye Hospital, Henan Eye Institute, People's Hospital of Zhengzhou University, Zhengzhou, China.
Xu Y; Department of Ophthalmology of Henan Provincial People's Hospital, Henan Eye Hospital, Henan Eye Institute, People's Hospital of Zhengzhou University, Zhengzhou, China.
Pokaż więcej
Źródło:
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde [Ophthalmologica] 2023; Vol. 246 (2), pp. 81-89. Date of Electronic Publication: 2023 Jan 27.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Ranibizumab*/therapeutic use
Retinopathy of Prematurity*/diagnosis
Retinopathy of Prematurity*/drug therapy
Recombinant Fusion Proteins*/therapeutic use
Humans ; Infant ; Infant, Newborn ; Intravitreal Injections ; Prospective Studies ; Vascular Endothelial Growth Factor A/blood ; Vascular Endothelial Growth Factor B/blood ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Risk assessment of drug-drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach.
Autorzy:
Vugmeyster Y; EMD Serono, Billerica, Massachusetts, USA.
Locke G; EMD Serono, Billerica, Massachusetts, USA.
Helwig C; The Healthcare Business of Merck KGaA, Darmstadt, Germany.
Rolfe PA; EMD Serono, Billerica, Massachusetts, USA.
Dong JQ; EMD Serono, Billerica, Massachusetts, USA.
Venkatakrishnan K; EMD Serono, Billerica, Massachusetts, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2022 Dec; Vol. 15 (12), pp. 2838-2843. Date of Electronic Publication: 2022 Oct 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 CYP3A*/metabolism
Recombinant Fusion Proteins*/pharmacology
Humans ; Drug Interactions ; Risk Assessment ; RNA, Messenger/genetics ; Transforming Growth Factor beta
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals.
Autorzy:
Thébault S; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Lejal N; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Dogliani A; Centre National de la Recherche Scientifique, Architecture et Fonction des Macromolécules Biologiques, UMR, Marseille, France.
Donchet A; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Urvoas A; Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette cedex, France.
Valerio-Lepiniec M; Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette cedex, France.
Lavie M; Université Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.
Baronti C; Unité des Virus Émergents (UVE), Aix Marseille Université, IRD 190, INSERM 1207, Marseille, France.
Touret F; Unité des Virus Émergents (UVE), Aix Marseille Université, IRD 190, INSERM 1207, Marseille, France.
Da Costa B; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Bourgon C; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Fraysse A; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Saint-Albin-Deliot A; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Morel J; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Klonjkowski B; UMR Virologie, INRAE-ENVA-ANSES, École Nationale Vétérinaire d'Alfort, Université Paris-Est, Maisons-Alfort, Paris, France.
de Lamballerie X; Unité des Virus Émergents (UVE), Aix Marseille Université, IRD 190, INSERM 1207, Marseille, France.
Dubuisson J; Université Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.
Roussel A; Centre National de la Recherche Scientifique, Architecture et Fonction des Macromolécules Biologiques, UMR, Marseille, France.
Minard P; Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette cedex, France.
Le Poder S; UMR Virologie, INRAE-ENVA-ANSES, École Nationale Vétérinaire d'Alfort, Université Paris-Est, Maisons-Alfort, Paris, France.
Meunier N; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Delmas B; Unité de Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2022 Sep 06; Vol. 18 (9), pp. e1010799. Date of Electronic Publication: 2022 Sep 06 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Angiotensin-Converting Enzyme 2*/chemistry
Angiotensin-Converting Enzyme 2*/metabolism
Recombinant Fusion Proteins*/pharmacology
Recombinant Fusion Proteins*/therapeutic use
Spike Glycoprotein, Coronavirus*/metabolism
COVID-19 Drug Treatment*
Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; Humans ; Peptidyl-Dipeptidase A/metabolism ; Protein Binding ; Recombinant Proteins/pharmacology ; Recombinant Proteins/therapeutic use ; SARS-CoV-2/genetics
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo.
Autorzy:
Zhang H; Department of Surgery, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, Hebei, China.; Department of Oncology &Surgery, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, 050051, Hebei, China.; Department of Surgery, Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China.
Ye X; Department of Surgery, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, Hebei, China.; Department of Oncology &Surgery, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, 050051, Hebei, China.
Wen J; Department of Oncology &Surgery, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, 050051, Hebei, China.
Cai Z; Hebei Cell Therapy Technology Innovation Center, HOFOY Medicine Hebei Co., LTD, 238 Yangzi River Avenue, Shijiazhuang, 050000, China.
Li Y; Department of Surgery, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, Hebei, China.; Department of Oncology &Surgery, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, 050051, Hebei, China.
Zhang M; Hebei Cell Therapy Technology Innovation Center, HOFOY Medicine Hebei Co., LTD, 238 Yangzi River Avenue, Shijiazhuang, 050000, China.
Shen L; Hebei Cell Therapy Technology Innovation Center, HOFOY Medicine Hebei Co., LTD, 238 Yangzi River Avenue, Shijiazhuang, 050000, China.
Cai J; Department of Surgery, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, Hebei, China. .; Department of Oncology &Surgery, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, 050051, Hebei, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jun 21; Vol. 12 (1), pp. 10461. Date of Electronic Publication: 2022 Jun 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Chemokine CCL19*/genetics
Chemokine CCL19*/pharmacology
Interleukin-7*/genetics
Interleukin-7*/pharmacology
Receptors, Chimeric Antigen*
Recombinant Fusion Proteins*/genetics
Recombinant Fusion Proteins*/pharmacology
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/genetics
Antibodies, Monoclonal/genetics ; Antibodies, Monoclonal/pharmacology ; Cell Line, Tumor ; Humans ; Receptor, ErbB-2/immunology ; Receptor, ErbB-2/metabolism ; Single-Chain Antibodies/genetics ; Single-Chain Antibodies/pharmacology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A synthetic protein as efficient multitarget regulator against complement over-activation.
Autorzy:
Ruiz-Molina N; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
Parsons J; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
Müller M; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
Hoernstein SNW; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
Bohlender LL; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
Pumple S; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.
Zipfel PF; Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany.; Institute of Microbiology, Friedrich Schiller University, Jena, Germany.
Häffner K; Faculty of Medicine, Department of Internal Medicine IV, Medical Center, University of Freiburg, Freiburg, Germany.
Reski R; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.; Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
Decker EL; Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2022 Feb 22; Vol. 5 (1), pp. 152. Date of Electronic Publication: 2022 Feb 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Complement Activation*
Blood Proteins/*metabolism
Complement Factor H/*metabolism
Complement System Proteins/*metabolism
Erythrocytes/*metabolism
Recombinant Fusion Proteins/*metabolism
Amino Acid Sequence ; Animals ; Bryopsida/genetics ; Bryopsida/metabolism ; COVID-19/epidemiology ; COVID-19/metabolism ; COVID-19/virology ; Complement Membrane Attack Complex/metabolism ; Humans ; Models, Molecular ; Pandemics/prevention & control ; Protein Binding ; Protein Conformation ; Recombinant Fusion Proteins/chemistry ; Recombinant Fusion Proteins/genetics ; SARS-CoV-2/physiology ; Sheep
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Robust Recombinant Expression of Human Placental Ribonuclease Inhibitor in Insect Cells.
Autorzy:
Flachner B; TargetEx Ltd., Madách I. u. 31/2., H-2120 Dunakeszi, Hungary.
Dobi K; TargetEx Ltd., Madách I. u. 31/2., H-2120 Dunakeszi, Hungary.
Benedek A; TargetEx Ltd., Madách I. u. 31/2., H-2120 Dunakeszi, Hungary.
Cseh S; TargetEx Ltd., Madách I. u. 31/2., H-2120 Dunakeszi, Hungary.
Lőrincz Z; TargetEx Ltd., Madách I. u. 31/2., H-2120 Dunakeszi, Hungary.
Hajdú I; TargetEx Ltd., Madách I. u. 31/2., H-2120 Dunakeszi, Hungary.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2022 Feb 08; Vol. 12 (2). Date of Electronic Publication: 2022 Feb 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Insecta/*genetics
Insecta/*metabolism
Placental Hormones/*biosynthesis
Recombinant Fusion Proteins/*biosynthesis
Animals ; Enzyme Stability ; Humans ; Placental Hormones/isolation & purification ; Placental Hormones/metabolism ; Plasmids ; Recombinant Fusion Proteins/isolation & purification ; Recombinant Fusion Proteins/metabolism ; Temperature
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Escherichia coli recombinant expression of SARS-CoV-2 protein fragments.
Autorzy:
McGuire BE; Department of Biochemistry and Microbiology, University of Victoria, STN CSC, PO Box 1700, Victoria, BC, V8W 2Y2, Canada.
Mela JE; Department of Biochemistry and Microbiology, University of Victoria, STN CSC, PO Box 1700, Victoria, BC, V8W 2Y2, Canada.
Thompson VC; Department of Biochemistry and Microbiology, University of Victoria, STN CSC, PO Box 1700, Victoria, BC, V8W 2Y2, Canada.
Cucksey LR; Department of Biochemistry and Microbiology, University of Victoria, STN CSC, PO Box 1700, Victoria, BC, V8W 2Y2, Canada.
Stevens CE; Department of Biochemistry and Microbiology, University of Victoria, STN CSC, PO Box 1700, Victoria, BC, V8W 2Y2, Canada.
McWhinnie RL; Department of Biochemistry and Microbiology, University of Victoria, STN CSC, PO Box 1700, Victoria, BC, V8W 2Y2, Canada.
Winkler DFH; Kinexus Bioinformatics Corporation, Vancouver, BC, Canada.
Pelech S; Kinexus Bioinformatics Corporation, Vancouver, BC, Canada.; Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Nano FE; Department of Biochemistry and Microbiology, University of Victoria, STN CSC, PO Box 1700, Victoria, BC, V8W 2Y2, Canada. .
Pokaż więcej
Źródło:
Microbial cell factories [Microb Cell Fact] 2022 Feb 05; Vol. 21 (1), pp. 21. Date of Electronic Publication: 2022 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Coronavirus Nucleocapsid Proteins/*genetics
Escherichia coli/*metabolism
Recombinant Fusion Proteins/*biosynthesis
SARS-CoV-2/*metabolism
Spike Glycoprotein, Coronavirus/*genetics
Antibodies, Viral/immunology ; Antigen-Antibody Reactions ; COVID-19/pathology ; COVID-19/virology ; Chromatography, High Pressure Liquid ; Coronavirus Nucleocapsid Proteins/metabolism ; Humans ; Mass Spectrometry ; Phosphoproteins/genetics ; Phosphoproteins/metabolism ; Receptors, Cell Surface/genetics ; Recombinant Fusion Proteins/analysis ; Recombinant Fusion Proteins/genetics ; Recombinant Fusion Proteins/immunology ; SARS-CoV-2/isolation & purification ; Spike Glycoprotein, Coronavirus/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 19502

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies